Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

NCT ID: NCT02362230


Title
Sun Yat-sen University Cancer Center
Purpose
Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in patients with metastatic triple-negative breast cancer that have received at least two prior treatments.
Details
This is a phase II, multi-center study. Sixty-seven patients are planned to be enrolled. All patients will receive Icotinib 125 mg BID administered for 8 weeks. Patients with a complete response, partial response or stable disease at that time may continue to be treated based on physician discretion. Follow up is then required until resolution or stabilization of any treatment-related toxicity, and patients with stable disease or objective responses must also continue evaluations until survived.
Conditions
Metastatic Breast Cancer
Keywords
Source
Sun Yat-sen University
Sponsors
Sun Yat-sen University
Status
Recruiting
Acronym
Last Updated
18 Dec 2016
URL
Official Link
Locations
China